Cynthia Strout

Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125, STF2.HA1 SI)

David N. Taylor, John J. Treanor, Cynthia Strout et al. · Vaccine · 2011 · 160 citations

Vaccination, Vaccine Development, Allergy +10

Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine–naïve adults 60–64 years of age

Richard N. Greenberg, Alejandra Gurtman, Robert W. Frenck et al. · Vaccine · 2014 · 157 citations

Vaccinology, Vaccine Safety, Vaccination +7

Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study

Marc Gurwith, Michael Lock, Eve M. Taylor et al. · The Lancet Infectious Diseases · 2013 · 154 citations · Full text

No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease

Joseph A. Murray, Ciarán P. Kelly, Peter H.R. Green et al. · Gastroenterology · 2016 · 131 citations · Full text

Difference Between Latiglutenase, Villous Atrophy, Clinical Presentation +3

Immunogenicity and safety of Fluzone® intradermal and high-dose influenza vaccines in older adults ≥65 years of age: A randomized, controlled, phase II trial

Peter H. Tsang, Geoffrey J. Gorse, Cynthia Strout et al. · Vaccine · 2013 · 90 citations · Full text

Immunology, Immunodominance, Flu Vaccination +22